Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

NAFLD-the silent epidemic: NAFLD, caused by excessive fat accumulation in the liver, is now the most common chronic liver ...

Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be ...

A new study published in the journal of Nature Scientific Reports showed that the patients with hypothyroidism have increased ...

Alcoholic and non-alcoholic fatty liver disease (NAFLD) are well-known risk factors for colorectal cancer (CRC). NAFLD has ...

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, metabolic ...

March 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced new 'in ...

Recent figures show that around 63% of UK adults are either overweight or obese, and it's estimated that one in three have early-stage non-alcoholic fatty liver disease (NAFLD). NAFLD is a term ...

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...